PAVmed Q2 EPS $(0.14) Misses $(0.10) Estimate
PAVmed (NASDAQ:PAVM) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.10) by 40 percent. This is a 7.69 percent decrease over losses of $(0.13) per share from the same
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 11)
Earnings Scheduled For August 12, 2021
Companies Reporting Before The Bell
• Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter.
PAVmed Reports Its Lucid Diagnostics Subsidiary Launches First Lucid Test Centers
PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that its majority owned
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck’s Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 9)
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
Stocks That Hit 52-Week Highs On Thursday
Thursday's morning session saw 167 companies set new 52-week highs.